Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study
- PMID: 15042114
- DOI: 10.1038/sj.jhh.1001704
Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study
Abstract
This was a double-blind, randomized, placebo-controlled multicenter, titration-to-effect study of eprosartan in patients > or =60 years of age with isolated systolic hypertension. The study consisted of a 3 to 5-week placebo run-in period, a 13-week double-blind treatment period (6-week titration with eprosartan 600-1200 mg/day, 3-week maintenance, 4-week combination therapy with hydrochlorothiazide/HCTZ 12.5 mg), and a follow-up period within 5-7 days of last treatment dose. Overall, 283 patients (placebo/P: 135; eprosartan /E: 148) were randomized [female patients-P: 55.6%, E:54.7%; white-P:66.7%, E:67.6%). Mean sitting systolic blood pressure (SitSBP) at baseline was comparable (P: 170+/-0.8 mmHg; E: 171+/-0.8 mm Hg). At monotherapy end point, eprosartan produced a significant reduction in SitSBP (E: 16.1 mmHg vs P: 8.4 mmHg; P<0.0001). In all, 57.4% of patients responded to eprosartan monotherapy. Among nonresponders, the addition of HCTZ resulted in a decrease in SitSBP from baseline (E: 21.7 mmHg; P: 14.4 mmHg; P<0.002). Reductions were also noted in Standing SBP (monotherapy: P<0.001; combination therapy: P=0.03). No reductions in SitDBP >4 mmHg were found during the study. Age, gender, and race did not have any impact on the results. Post hoc analysis showed a reduction in pulse pressure from 87.3 to 78.2 mmHg with placebo and from 87.6 to 70.7 mmHg with eprosartan monotherapy. Treatment with eprosartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated, with dizziness and asthenia being the most common side effects.
Similar articles
-
Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).Adv Ther. 2010 Jun;27(6):365-80. doi: 10.1007/s12325-010-0032-7. Epub 2010 Jun 16. Adv Ther. 2010. PMID: 20556561 Clinical Trial.
-
Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.Can J Cardiol. 2004 Oct;20 Suppl C:6C-10C. Can J Cardiol. 2004. PMID: 16807617 Clinical Trial.
-
Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.Curr Med Res Opin. 2001;17(1):8-17. Curr Med Res Opin. 2001. PMID: 11464450 Clinical Trial.
-
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.J Hypertens Suppl. 2002 Feb;20(1):S21-5. J Hypertens Suppl. 2002. PMID: 11996196 Review.
-
Safety and tolerability of eprosartan in combination with hydrochlorothiazide.Drug Saf. 2002;25(8):599-611. doi: 10.2165/00002018-200225080-00005. Drug Saf. 2002. PMID: 12113644 Review.
Cited by
-
Eprosartan: a review of its use in hypertension.Drugs. 2009;69(17):2477-99. doi: 10.2165/11203980-000000000-00000. Drugs. 2009. PMID: 19911859 Review.
-
Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.Eur J Clin Pharmacol. 2012 Feb;68(2):195-205. doi: 10.1007/s00228-011-1107-3. Epub 2011 Sep 1. Eur J Clin Pharmacol. 2012. PMID: 21881888
-
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003822. doi: 10.1002/14651858.CD003822.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843650 Free PMC article.
-
Clinical profile of eprosartan: a different angiotensin II receptor blocker.Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. doi: 10.2174/187152508785909500. Cardiovasc Hematol Agents Med Chem. 2008. PMID: 18855637 Free PMC article. Review.
-
Eprosartan: a review of its use in the management of hypertension.Drugs. 2005;65(16):2355-77. doi: 10.2165/00003495-200565160-00012. Drugs. 2005. PMID: 16266204 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical